Making a Difference Worldwide

Focus areas

• Anaesthesia and Analgesia
• Dermatology
• Endocrinology
• Internal Medicine
• Cardiovascular
• Nutrition

What Differentiates Us

Our broad portfolio serves specialist therapy areas and is predominantly prescription only medicines rather than ‘blockbuster’ vaccines or regular healthcare treatments. As such, our portfolio is largely non-discretionary in nature and also benefits from a high degree of novelty.

We also offer a specialist range of pet food for dogs and cats under our Speciifc® brand, providing high quality nutrition to support many of the therapeutic conditions treated by our pharmaceuticals.

Focus Areas

• Water soluble antibiotics
• Vaccines
• Lameness
• Pain management

What Differentiates Us

Our focus is on water soluble antibiotics and vaccines, both of which help to maintain productivity of food producing animals globally in the face of a rising world population.

We also play a prominent role in looking to develop products aimed at improving animal welfare and husbandry.

Focus Areas

• Lameness
• Pain management

What Differentiates Us

The equine market is relatively small and serviced by very few animal health companies.

Dechra’s specialism in lameness and pain management for horses and ponies allows us to be a leading brand within equine pharmaceuticals and we offer a range of highly efficacious products to support the equine veterinarian.

Our people are the heartbeat of our business and they reinforce our Culture every single day, helping to create the special place to work that Dechra is.

All 2,457 employees are crucial to our success. Whether it is the highly talented scientists in our Product Development and Regulatory Affairs teams, front line manufacturing employees across our various sites, the hugely passionate sales representatives or the teams providing central support functions in our Corporate division, everyone who works for Dechra has an important role to play in delivering our success year after year.

We empower our people to take responsibility and foster a collaborative, supportive and ambitious environment within which to perform to the best of their ability.

We are rightly proud of the fact that we are a Living Wage employer globally. Never has this been more important than today given the cost of living challenges being felt by many people worldwide.

In addition to ensuring an appropriate approach to reward and recognition, we also provide a wide range of other support to employees. This is all underpinned by a shared passion for fulfilling our purpose every single day.

We invest heavily in training and development, which includes our internal digital learning platform, Delta, and encourage employees to take responsibility for their own career knowing that Dechra will support and encourage those endeavours wherever possible.

2,457

Employees
Globally

26

Countries with
Sales Team

7,807

Delta Training
Hours

55%

Females in
Workforce

In January 2022, we launched our inaugural Future Facing Leaders programme designed to help develop our internal talent and create a sustainable pipeline for future leaders within the business.

The current cohort of 24 employees, taken from across the Group both in terms of geography and business function, have now reached the end of the course.

The programme has been an undoubted success over the past two years. Much has been learnt, both by the participants themselves on an individual level but

also by the wider business and the Senior Executive Team thanks to the candid and thoughtful feedback provided during the various sessions.

As the business enters a new chapter in its history, these employees will have a crucial role to play in helping to keep Dechra successful.

We are currently developing plans for the next iteration of the programme so that it remains closely aligned to the business strategy over the coming years and addresses the need to maintain the flow of high calibre individuals who can enact that strategy.

Our portfolio, particularly within CAP, has a high degree of novelty and addresses conditions in relatively niche therapeutic areas. This makes Dechra the partner of choice for many veterinarians when it comes to certain conditions and allows our sales teams to engage with them on products that can help grow their own practice rather than just price or the role of generic alternatives. The fact that a large proportion of our sales representatives are qualified veterinarians in their own right only adds to the credible and differentiated nature of our portfolio.

Dechra collaborates with veterinary professionals, academic institutions and industry experts to enhance our understanding of animal health and develop innovative solutions. Through this collaboration we foster knowledge exchange and develop products and services that address emerging healthcare challenges and meet the evolving needs of the veterinary community. Our pipeline of potential new products is as strong as ever and has an increasing focus on bringing novel CAP products to market over the coming years.

206

New Marketing
Authorisations

5,994

Marketing
Authorisations

205,012

CPD Training
Hours Provided

16,300

Technical
Support Enquiries

training, support and information that helps them help animals. We provide accessible science that enables veterinarians to communicate with owners and farmers better. It is this perspective that makes us a preferred supplier. Understanding customers is built into our business model. We give veterinarians what they need, from everyday evidence-based treatments to knowledge on rarer diseases.

To ensure our growth, we are not just an animal pharmaceutical company. We are the veterinary professional’s pharmaceutical company.

Dechra’s heritage is as a UK based veterinary distribution business, but by 2013 we had become a fully focused veterinary pharmaceutical business. Through a combination of both organic growth and a number of business acquisitions, we have since grown to become a truly global business with operations in a total of 88 countries.

Whilst we already have a strong presence in the well developed markets of Western Europe and North America, these markets continue to represent significant further growth opportunities; particularly the largest animal health market in the world, the US. We already have a talented US sales team but intend to invest in more representatives commensurate with our future growth aspirations.

In addition, we continue to extend the reach of our products to animal health markets worldwide through our International division. This is typically achieved by using local distribution partners to obtain a foothold in new markets initially, before bringing operations in-house once sufficient critical mass has been achieved.

Dechra’s revenue profile differs by country depending on underlying market dynamics and the maturity of our operations. For example, the UK market is very mature whereas in Brazil sales are heavily weighted towards FAP; indicative of both the large numbers of livestock in Brazil but also the nascent companion animal market that is slowly developing.

We have a significant opportunity to grow market share in product categories where we are currently underweight, but this will likely be achieved slowly given market dynamics and the time taken to register products in each country.

Education of veterinarians, increasing brand awareness and leveraging our novel portfolio will all remain crucial to our future success and allow us to capitalise on the strong structural growth drivers within the animal health industry.

With increasing numbers of both companion and food producing animals, which are also living longer, Dechra’s Purpose has never been more relevant. Through our focus on innovation and providing a portfolio of products that can be used across an animal’s entire lifetime, we will support veterinarians to administer the best possible clinical care.

hair loss to excessive urination, increased appetite to excessive panting, and lethargy. Additionally, the online investigation room had a symptoms checklist designed to help dog owners uncover their dog’s symptoms, as well as a treatment and monitoring logbook.

The feedback received from veterinarians was extremely positive, who noted that it really helped pet owners recognise the signs of Cushing’s.

In addition to being a successful campaign from an animal health industry perspective, it also won two awards at the B2B Marketing’s Elevation Awards in the USA.